U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938606) titled 'MG-K10 in Pediatric Atopic Dermatitis (6-12 Years)' on Oct. 27.
Brief Summary: A Phase Ib/II Study of MG-K10 in Pediatric Patients (6-12 Years) with Moderate to Severe Atopic Dermatitis
Primary Objective:
To evaluate the safety of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
To evaluate the pharmacokinetic (PK) characteristics, preliminary efficacy, pharmacodynamic (PD) characteristics, and immunogenicity of MG-K10 humanized monoclonal antibody injection in pediatric patients with moderate-to-severe AD.
Study Start Date: Dec., 2026
St...